COMPANY

Immix Biopharma

HQ: Los Angeles, CA source · immixbio.com ↗

Keywords: CAR-T

Location: Los Angeles, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Sep 30, 2026 Raise Follow-on offering: $125M (total, as published), announced Sep 30, 2026. Source: company release on GlobeNewswire. source ↗
May 22, 2026 Raise Follow-on offering: $150M (total, as published), announced May 22, 2026. Source: company release on GlobeNewswire. source ↗
Dec 9, 2025 Raise Follow-on offering: $100M (total, as published), announced Dec 9, 2025. Source: company release on GlobeNewswire. source ↗
Sep 8, 2025 Raise Private placement: amount not published, announced Sep 8, 2025. Source: company release on GlobeNewswire. source ↗
Feb 3, 2023 Trial start Phase 1/Phase 2: Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors source ↗

Raised: $375.0M. Last 2 years.

Sep 30, 2026 Follow-on offering: $125M (total, as published), announced Sep 30, 2026. Source: company release on GlobeNewswire. source ↗
May 22, 2026 Follow-on offering: $150M (total, as published), announced May 22, 2026. Source: company release on GlobeNewswire. source ↗
Dec 9, 2025 Follow-on offering: $100M (total, as published), announced Dec 9, 2025. Source: company release on GlobeNewswire. source ↗
Sep 8, 2025 Private placement: amount not published, announced Sep 8, 2025. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05840835	Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	Feb 3, 2023	Jan 24, 2024 (estimated)